COMPOSITION

One effervescent tablet contains:
Glucosamine sulphate – 750 mg
Chondroitine sulphate – 600 mg
Methylsulfonylmethane – 750 mg
Manganous gluconate dehydrate – 20 mg
Calcium – 500 mg
Vitamin D3 – 400 IU

THERAPEUTIC INDICATIONS

- Degenerative dystrophic diseases of joints and spine (including osteochondrosis);
- Osteoarthrosis of I-III stage;
- Prophylaxis and complex treatment of osteoporosis and its complications (fractures);
- Compensation of calcium and D3 vitamin deficiency;
- As a part of rehabilitation actions following joint traumas.

ADVERSE EFFECTS

CNS disorders: dizziness, headache, somnolence, insomnia.
Metabolism disorders: hypercalcemia, hypercalciuria.
Gastrointestinal disorders: meteorism, diarrhea, constipation, upper abdominal pains, nausea, abdominal pains.
Other: tachycardia, peripheral edema, scelalgia, allergic reactions.

DOSAGE AND ADMINISTRATION

Protecta is orally administered with mo regard to food intake. One tablet should be completely dissolved in 200 ml of water of room temperature. Drink immediately after the dissolution.
For prophylaxis, as a part of complex therapy of osteoporosis, as well as calcium and D3 vitamin deficiency, 1 tablet of Protecta is administered 1-2 times daily. The duration of therapy and dosage regimen is determined according to doctor’s recommendations.
In treatment of degenerative dystrophic diseases of joints and spine (including osteochondrosis) and osteoarthrosis of I-III stage, during three first weeks 1 tablet of Protecta is administered twice daily, and during subsequent days 1 tablet is administered once daily. The duration of treatment is 3-6 months. If needed, individually assigned course of retreatment may be prescribed.

INTERACTION WITN OTHER MEDICINAL PRODUCTS

Protecta depresses the action of semisynthetic penicillin and chloramphenicol, potentiates the action of anticoagulants. Administered concurrently with phenytoin or barbiturates, the decreased activity of Vitamin D may be observed. Colestyramine or mineral oil or agricultural oil laxatives decrease the absorption of D3 vitamin.
Applied concurrently with biophosphonates or sodium fluoride, the intake interval should be no less than 2 hours. Applied concurrently with oral tetracycline, the intake interval should be no less than 3 hours.

MANUFACTURED FORM

Effervescent tablets.
20 effervescent tablets in polypropylene tube, closed with propylene stopper with silica gel.
1 tube with a leaflet in carton box.